Zoetis Q2 revenue $2.5B (+4% reported, +8% organic); raises FY2025 guidance

Zoetis Inc.

2025-Q2 EPS reported $3.02 revenue$4,680,000,000

Reported net income $718M ($1.61 diluted EPS), up 15% YoY; adjusted EPS $1.76, up 13%.
U.S. segment revenue $1.4B (+4% reported, +7% organic); companion animal product sales up 9%.
International segment revenue $1.1B (+3% reported, +9% organic); livestock sales up 10% organic.
Raised FY2025 revenue guidance to $9.45-9.60B (organic growth 6.5-8.0%); adjusted EPS $6.30-6.40.
Simparica Trio gained new label in Japan; avian influenza vaccine conditionally licensed for U.S. dairy cattle.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.